United Therapeutics Corporation
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $417.9M | $713.7M | $651.6M | $340.1M | $174.6M | $304.4M | $217.9M | $105.9M |
| Depreciation & Amortization | $31.0M | $31.6M | $32.9M | $32.2M | $31.3M | $27.1M | $20.5M | $17.9M |
| Depreciation | $30.5M | $31.0M | $31.8M | $30.8M | $28.6M | $25.0M | $18.2M | $17.6M |
| Amortization | $500.0K | $600.0K | $1.1M | $1.4M | $2.6M | $2.1M | $1.7M | $1.6M |
| Stock-Based Compensation | $73.5M | $12.1M | $280.3M | $190.1M | $320.8M | $30.1M | $-15.7M | $113.9M |
| Net Cash from Operating Activities | $474.2M | $643.6M | $382.8M | $355.3M | $425.3M | $323.6M | $250.2M | $211.5M |
| Investing Activities | ||||||||
| Capital Expenditures | $86.3M | $38.0M | $49.8M | $47.4M | $31.9M | $111.9M | $36.0M | $18.6M |
| Business Acquisitions | — | $5.2M | — | — | — | — | $3.5M | — |
| Net Cash from Investing Activities | $-835.6M | $48.3M | $503.6M | — | — | $-163.4M | $-121.3M | $-209.2M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $250.0M | $500.0M | $394.5M | $483.1M | $42.4M | $188.0M | $212.0M | — |
| Net Cash from Financing Activities | $43.3M | $-497.7M | $-447.0M | — | — | $-169.1M | $-218.1M | $146.8M |
| Net Change in Cash | $-317.9M | $191.2M | $434.1M | $113.4M | $124.9M | $-8.6M | $-89.5M | $151.8M |
| Free Cash Flow | $387.9M | $605.6M | $333.0M | $307.9M | $393.4M | $211.7M | $214.2M | $192.9M |